Partners
Biofourmis is a global leader in virtual care and digital therapeutics, offering innovative solutions that enable clinicians to deliver personalized predictive care to patients outside of a traditional hospital, clinic, or clinical research environment.
Learn More
BrightInsight provides the leading global regulated digital health platform for biopharma and medtech. Every line of code of our BrightInsight Platform is built under a Quality Management System to support and optimize regulated drugs, devices and software through integrated data and actionable insights to enable customers to drive increased patient adherence and engagement. The BrightInsight™ Platform uses software and services to capture, transmit and analyze data from CE-marked and FDA-regulated medical devices, combination products, apps and Software as a Medical Device, in compliance with global security, privacy and regulatory requirements. Deployed as a managed service, the platform accelerates time to market for biopharma and medtech companies, reduces the cost of implementation and maintenance versus a custom solution, and scales across products and global markets.
Learn More
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug and play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security and reusability of data for researchers worldwide.
Learn More
Curebase is a leading provider of decentralized clinical research software and services for digital therapeutics. Curebase enables any patient and any healthcare provider to be part of a clinical study, accelerating enrollment and enabling novel study designs with diverse populations. Curebase operates as a complete eClinical software platform, virtual research site, and full-service CRO.
Learn More
Decimal.health is a specialized digital health consulting firm that creates and implements
strategies to launch and grow digital health products and services. Through our deep network
and expertise in US healthcare delivery and regulations, we help digital health businesses
navigate the complex DTx and FDA regulatory path and gain traction with investors and
customers
Learn More
We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.
The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.
We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.
Learn More
Focusing on remote physiotherapy and digital health platforms, Kemtai’s software platform can run on any device and guide users as if a personal therapist was right there with them.
Kemtai provides immediate feedback, corrective guidance and qualitative scoring, creating a hyper-personalised, effective and engaging experience.
Learn more
L&T Technology Services Limited (LTTS) is a global leader in Engineering, technology, and R&D (ER&D) services. With over 900+ filed and multiple innovations such as World’s First 40ATM angioplasty device, LTTS is the preferred technology partner for 57 of the Global Top 100 ER&D spenders. For our Healthcare customers, we offer tested technology and consulting solutions that foster collaboration and digital innovation that leverages on our in-depth and practical knowledge in Digital Therapeutics (DTx), Software as a Medical Device (SamD), Clinical Decision Support Systems (CDSS), Clinical Research, Decentralized Clinical Trials (DCT), Regulatory Compliance, Analytics, Product Development, and Lifecycle Management.
Learn More
Ieso is a data-driven AI healthcare company pioneering next-generation digital therapeutics to improve mental health outcomes and access to care.
The company is developing a pipeline of AI-driven evidence-based mental health assessment tools and solutions to democratize access to mental health therapy at scale. With a network of more than 600 fully qualified therapists, ieso provides virtual care (or telehealth) serving more than 20 million adults through the UK National Health Service (NHS), delivering more than 460,000 hours of cognitive behavioral therapy (CBT).
The company has analyzed over 500 million datapoints to decode the active ingredients of therapy to develop scalable digital therapeutics. ieso’s research has been published in several peer-reviewed journals including the Lancet and JAMA, shaping our understanding of scalable digital mental healthcare solutions.
Learn More
IQVIA is a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward. Together with the companies we serve, we are enabling a more modern and effective healthcare system and creating breakthrough solutions that transform business and patient outcomes.
Learn More
TopLine Power® is what Simon-Kucher is all about. We help clients grow revenue through optimization of strategy, pricing, marketing, and sales across industries.
We are a thought leader in these topics at the intersection of digitalization and life sciences, positioning our clients thrive in the healthcare industry of the future.
Learn More
SoftServe is a trusted technology advisor and provider. We enable our clients across the healthcare continuum to build transformative patient experiences, gain data insights, and accelerate business outcomes. SoftServe’s experts deliver innovation, quality, and speed built on a foundation of empathetic, human-focused experience design.
Learn More
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 35 years of experience and 10,000-plus ZSers in more than 25 offices worldwide, we are passionately committed to helping companies and their customers thrive.
Learn More
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 35 years of experience and 10,000-plus ZSers in more than 25 offices worldwide, we are passionately committed to helping companies and their customers thrive.
Learn More
DTxCC: a boutique consultancy focused solely on Digital Therapeutics and Digital Health commercialization
We specialize in go-to-market strategy development:
- Market Access and Reimbursement
- Business models development
- Data monetization
Our Payer Advisory Council provides actionable insight
Custom qualitative research
- One-one-one interviews
Advisory board meetings
- Virtual
- Live face-to-face meetings
Learn More
Bold Insight is a UX and human factors research agency based in Chicago. Our projects span the product development life cycle, we conduct user research informing early product design to global human factors validation. We work with digital, next-generation technology—medical devices to mobile apps, IFUs to customer journeys.
Learn More
Curavit is a “Virtual CRO” that designs and executes decentralized - or “virtual” - clinical trials. Curavit leverages emerging technologies in digital health, cloud computing, and data science to recruit, engage, and monitor diverse patient populations from wherever they live, work, or study; eliminating the need for physical infrastructure and travel, while increasing data quality. Curavit brings together the world’s leading researchers, enrolls previously untapped and underserved patient populations, applies machine learning algorithms to health and social engagement information to recruit participants, and leverages leading telehealth, patient data, and medical device technologies. Curavit’s central virtual site supports remote monitoring and is always audit ready.
Learn More
Innovaccer Inc., the Health Cloud company, is dedicated to accelerating innovation in healthcare. The Innovaccer® Health Cloud unifies patient data across systems and care settings, and empowers healthcare organizations to develop scalable, modern applications that improve clinical, financial, and operational outcomes. Innovaccer’s solutions have been deployed across more than 1,600 care settings in the U.S., enabling more than 96,000 providers to transform care delivery and work collaboratively with payers and life sciences companies. Innovaccer has helped its customers unify health records for more than 39 million people and generate over $1B in cumulative cost savings. Innovaccer is the #1 rated Data and Analytics Platform by KLAS, and the #1 rated population health technology platform by Black Book.
Learn More
Charles River Associates (CRA) is a leading global consulting firm that offers economic, financial, and strategic expertise to major law firms, corporations, accounting firms, and governments around the world. Our experts bring a unique combination of cutting-edge research, state-of-the-art methods, and proven experience to bear on our clients’ most complex challenges.
Learn More
At our core is perseverance, a fierce determination to overcome any obstacle regardless of setbacks, on behalf of patients and their loved ones. We place greater value on what we can achieve together than on what we can do alone because the needs of those we serve always come first. We will not be bound by doing what’s been done before. Instead, we free ourselves from preconceived notions to discover solutions that advance patient care. Our mission is clear: Otsuka-people, creating new products for better health worldwide.
Learn More
JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.
We seek breakthroughs at the intersection of digital technology and neuroscience that are influencing the human experience, such as augmented reality, artificial intelligence, immersive gaming, and closed-loop human-computer systems.
Our portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise.
Learn More
Voluntis is an Aptar Pharma company and part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Voluntis creates digital therapeutics that empower people with chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Voluntis’ solutions combine mobile and web apps, using clinical algorithms to deliver personalized recommendations to patients and their care teams to adjust treatment dosage, manage side effects or monitor symptoms.
Leveraging its Theraxium technology platform, Voluntis designs digital therapeutics solutions across multiple areas, including oncology and diabetes. Based in Cambridge, MA, and Paris, France, Voluntis is a founding member of the Digital Therapeutics Alliance.
Learn More about Voluntis
Learn More about Aptar
DTx Annual Pass
Want to secure your place at DTx conferences for the lowest possible price? Take a look at the brand new DTx Annual Pass!
Find out how you can get the guaranteed best price on tickets and unlock a host of exclusive benefits here:
About Us
DTx East 2022 is aligned with the digital therapeutics industry and its efforts to establish digital within healthcare.
Dedicated to tackling key challenges around reimbursement, regulation, physician adoption, patient engagement and more, DTx East 2022 is set to empower the experts and catalyze the digital evolution of healthcare.
DTx East 2022 is back with a bang! Bringing you 3 full days of cutting-edge content and an industry leading speaker faculty, this event provides you with a one-stop shop of all things digital therapeutics ensuring you leave the event with key takeaways and the knowledge to accelerate your own digital journey. We’ve got a lot to catch up on and DTx East has got you covered!
The time has come to meet in-person once again! Join your peers for live presentations, engaging discussions and face-to-face networking. Step away from the screen for 3 days of industry-defining discussions and catch up with old and make new connections within the field. With some of the audience tuning in virtually, use our dedicated session to network with industry leaders from across the globe.
Experts from every stakeholder within the digital therapeutics space will be descending on Boston in September. Join your peers from leading DTx companies, Pharma, Payers, Providers, Government Bodies, Policy Makers and more!
DTx conferences are excellent places to collaborate with top leaders and stay current on the often complex and evolving trends shaping our investments - all while being part of a passionate, growing community of entrepreneurs.
The DTx series is more than a conference – it’s become a community with mutual interest in advancing digital therapeutics.
The people I have met and the discussions I have had during and between sessions at past in-person DTx events have turned into friendships and business relationships that are the true highlights of the DTx events.. I am really looking forward to being part of the in-person interactions at this year’s DTx East.
DTx West 2021 did not disappoint! Even though this was a virtual conference the quality of presentations were stellar. Looking forward to DTx East!
DTx East 2022 Speaker Faculty
Meg is passionate about driving change by collaborating with physicians, technology leaders and solution innovators to improve health care. She has served in product development and business development leadership roles at the AMA and most recently is responsible for driving the roadmap of initiatives that support the AMA’s digital health and medicine strategy. In addition, she has led partnerships and innovation related initiatives, such as the inaugural AMA Healthier Nation Innovation Challenge, the establishment of the AMA Interaction Studio at MATTER, the AMA Physician Innovation Network that enables entrepreneurs and physicians to collaborate on the development of new solutions, the AMA Digital Health & Telehealth Implementation Playbook series, AMA Digital Health research and The Telehealth Initiative with collaborators. She participates on the Advisory Board for MATTER, MassChallenge HealthTech, HealthTech Arkansas, Together.Health and as a TEDMed Research Scholar. She also participates on the Editorial Review Board of The Telehealth and Medicine Today Journal.
Meg has spoken at national conferences such as Health 2.0, Connected Health, HLTH, American Telemedicine Association National Conference, AMA State Advocacy Conference and contributes as speaking faculty for Columbia Business School’s Digital Health program curriculum. She has articles published in Health Affairs, Harvard Business Review and Nature Digital Medicine.
Prior to AMA, Meg worked in the Consumer Product & Retail vertical at Capgemini and at SmithBucklin Corporation for various business and health care clients.
Kamal is an industry leader with 15+ years of experience in digital health from a provider perspective, most recently at MassGeneral Brigham, with a background in digital health strategy, product design and clinical research and validation. Kamal has developed and implemented 100+ digital health programs and is widely published in the value digital health can bring to healthcare delivery.
Alyssa Reisner is a Lead Director and Principal at CVS Health Ventures. In her role, she sources, evaluates, and executes investments in innovative health care companies. She has built strategic relationships and executed investments for CVS Health in areas spanning DTx, women’s health, behavioral health, COVID-19 initiatives, and more.
Katie joined AbbVie in May 2021 as a Director of Regulatory Affairs for the newly formed Digital &
Medical Device Team in the Emerging Technology & Combination Product group. In this role, Katie and
her team support internally developed SaMD projects providing regulatory strategy during development
and GRL support prior to global launch. In addition, Katie is the lead Device Regulatory for the ABBV-
RGX-314 partnership between AbbVie and Regen X Bio supporting both key ancillary devices required
for the Subretinal and Suprachoroidal delivery of the biologic.
Prior to joining AbbVie, Katie held a biomedical engineer and lead reviewer position the US FDA Center
for Devices and Radiological Health (CDRH) in the Cardiovascular Device Division (DCD) in the Office of
Device Evaluation (ODE) from 2006 until 2015. In this role she was the lead reviewer for interventional
cardiovascular devices including guidewires, guide catheters, bare metal, drug eluting and bioabsorbable
stents. After completing the Leadership Readiness program in 2015, Katie joined the Office of Orphan
Products Development (OOPD) in the Commissioner’s Office where she led review of the Humanitarian
Use Device (HUD) designations, supported the Pediatric Device Consortium and Orphan Clinical Trials
grants. Her last official role at the Agency took her back to CDRH where she headed the partnership with
the Medical Device Innovation Consortium (MDIC) in the External Partnerships sector and supported
regulatory science project development across multiple initiatives including Digital Health, In Vitro
Diagnostics, Early Feasibility Studies (EFS), Case for Quality and Science of Patient Input.
Katie holds her undergraduate degree from the University of Pittsburgh (cum laude) in Biomedical
Engineering (2004) and her master’s degree from Maquette University and the Medical College of
Wisconsin in Healthcare Technology Management (2005). Katie resides in NW Washington DC with her
husband, Atiq, and twin boys, Isaac and Isaiah.
Alyssa Dietz, Ph.D. is senior director of Precision Care Strategy at Twill (formerly Happify Health). She is a licensed clinical psychologist who made her way to the digital therapeutics industry after working as a professor and practicing psychologist. She provided Cognitive Behavioral Therapy and Motivational Interviewing for the treatment of substance use disorders and health-related behavior change more broadly. Her research lab studied digital intervention and prevention programs and the use of digital tools to increase access to evidence-based care. She was an assistant professor first at Penn State and later Austin College where she trained future psychological scientists and therapists, directed a research lab, and first learned to translate complex topics to digestible information. Later, she joined Pear Therapeutics where she worked as a Medical Science Liaison, and served as a scientific and clinical resource to a range of stakeholders, including physicians, payers, advocacy groups, and others. She is passionate about revolutionizing access to evidence-based care.
Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.
Kate is a Senior Principal in the EMEA Consulting team at IQVIA, currently based in London. She has over 12 years of consulting experience, working with a broad range of pharmaceutical, biotechnology, diagnostic, and digital health clients. Kate has expertise in market access strategy, launch pricing, companion diagnostics and access strategy in digital health. Kate holds a B.A. from Princeton University in Molecular Biology
Aubrey Shick is a Sr. Digital Health Advisor in the Digital Health Center of Excellence (DHCoE) at FDA’s Center for Devices and Radiological Health (CDRH). Aubrey leads efforts related to digital health policy, transparency of AI/ML-enabled devices, and regulatory science for the DHCoE, promoting user-centered considerations in digital health. Before joining the DHCoE in 2021, Aubrey worked in industry leading product strategy, software user experience (UX) architecture, and validation programs for multiple wellness and digital health startups, Intel’s New Devices Group, and Medtronic. Aubrey’s product experience encompasses artificial intelligence (AI), virtual and augmented reality (VR/AR), wearable computing, embedded computing (IoT), and surgical robotics.
Innovator. Scientist. Thought leader. Technologist. Sleep and Circadian Sciences expert. Creator of Precision and Personalized Population Health. Voted top 100 most inspiring Black Scientists in America by Cell Press. I believe in health and wellness for all through disruptive and scalable innovation. Director of The Media and Innovation Lab, The MIL.
Whitney is a Director of Clinical Project Management. She oversees the implementation of multiple
clinical trials at Curebase, including some in digital therapeutics. She has worked in the decentralized
trial space for over 5 years and in clinical research for over 10.
Steve LoSardo is the vice president of Life Science Solutions and consulting at SoftServe. He’s a dynamic leader and visionary with more than 25 years of experience providing information technology solutions to consumers, life science, and healthcare companies. Steve focuses on working with clients to deliver innovative digital solutions based on web, mobile, voice, IoT, big data, AI/ML, and cloud technologies in the pharmaceutical, biotech, and payer spaces.
Jay Ahlman is Vice President of CPT Coding and Reimbursement Policy and Strategy for the American Medical Association (AMA). Jay joined the AMA in 1999 and has held various roles in healthcare strategy, policy and coding during his tenure. Since 2008, Jay has led the AMA group responsible for the maintenance of the Current Procedural Terminology (CPT) code set and is the lead staff to the CPT Editorial Panel for the AMA. During this time Jay has worked with the CPT Editorial Panel to lead many significant changes, including the evolution of CPT Literature Standards and the launch of new CPT coding sections including the Proprietary Laboratory Analyses (PLA) code section. Jay is also the lead staff to the AMA’s Digital Medicine Payment Advisory Group, which is an advisory body made up of 15 industry experts charged with creating solutions to enable the integration of digital healthcare and telehealth solutions into clinical practice. Most recently, Jay has been involved in the revision of the CPT Evaluation and Management coding structure and the addition of Remote Physiologic and Remote Therapeutic Monitoring codes to the CPT code set.
Smit J. Patel, PharmD serves as the Strategic Program Lead at the Digital Medicine Society (DiMe), a 501(c)(3) global non-profit organization dedicated to advancing digital medicine to optimize human health. His work focuses on applied approaches to the safe, effective, ethical, and equitable use of digital technologies to advance its evaluation and implementation in clinical research and care delivery. He is an Advisory Board member for the Brown-Lifespan Center for Digital Health and the Digital Therapeutic Alliance (DTA) and serves on advisory committees for digital health program(s) at the Association of Community Cancer Centers (ACCC), American Pharmacists Association (APhA), and HealthXL. He also serves on the steering committee for the APACMed Digital health reimbursement alliance.
Shaheen Lakhan, MD, PhD, FAAN, is a physician-scientist, biotech executive, and biopharma board
director with over 20 years of experience in healthcare, academia, and industry focusing on
neuroscience research and development. He is board-certified in both neurology and pain medicine,
with clinical training from Cleveland Clinic and Massachusetts General Hospital.
As an expert in patient-empowering clinical development from drugs to devices, Dr. Lakhan is keen
on transforming medicine and democratizing health care through prescription digital therapeutics
(Chief Medical Officer, Click Therapeutics) and novel drug-delivery platforms (Board Director,
SpineThera). He continues to serve patients as a practicing neurologist and pain specialist (Mount
Auburn Hospital, Cambridge Health Alliance) and is professor of neurology and neuroscience
(Western University, Virginia Tech).
Previously, Dr. Lakhan served as faculty of leading institutions (Harvard Medical School, Case
Western Reserve University), founding department chair and curricular dean (California University of
Science and Medicine), institutional review board chair (Arrowhead Regional Medical Center), chief
of pain management (Virginia Tech - Carilion Clinic), and executive/leadership positions in
biopharma (Sage Therapeutics, Zogenix) and biotech (The Learning Corp, Fern Health).
In addition to exemplary clinical service, Dr. Lakhan has an extensive research, education, advocacy,
and philanthropy portfolio. He has over 100 peer-reviewed publications, books, and book chapters.
For founding the Global Neuroscience Initiative Foundation, he was bestowed the Harvard Medical
School Dean’s Community Service Award. He was also conferred the President’s Call to Service
Award for Lifetime Achievement by President George W. Bush and The U.S. Congressional Award
Gold Medal by Senators Nancy Pelosi and Harry Reid. Further, California Governor Brown and
Virginia Governor Northam have appointed him to prestigious boards including the Health
Professions Education Foundation awarding more than $200 million towards closing the health
equity gap. Recognized by his peers, he was inducted as Fellow of the American Academy of
Neurology, the Academy’s highest designation.
Nick is a Principal in the US Consulting team at IQVIA, currently based in San Francisco. He has over 15 years of consulting and technology strategy experience, working with a broad range of healthcare clients. He has expertise in providing digital health and digital transformation solutions to payers, providers, and global healthcare and life sciences firms. Nick holds a B.S. from the Kelley School of Business at Indiana University.
Micaela Brandau is Vice President of Strategy and Corporate Development at AmerisourceBergen (AB), a
Fortune 10 global healthcare company with a foundation in pharmaceutical distribution and solutions. In
her role, Micaela is focused on working alongside teams at AB to develop and launch solutions aimed at
supporting biopharma companies and stakeholders involved in bringing new innovations to market. She
serves on the team leading the development of DTx Connect, a fully integrated ordering, dispensing and
fulfillment platform that aims to facilitate patient access to physician-ordered digital therapeutics and
diagnostics.
Prior to joining AmerisourceBergen in May 2022, Micaela worked at Johnson & Johnson for more than a
decade, most recently as the Global Strategic Marketing lead for Prostate Cancer. She earned an MBA
from the University of North Carolina at Chapel Hill and a BA from Boston College.
Dr. Caplan is a leading cannabis clinician, educator and advocate and board-certified family physician
with years spent advancing cannabis care and research. Founder of CED Clinic Intl & CED Foundation.
Trained at Tufts and BU, conducted studies at the UCLA Brain Mapping Center. Published in The New
England Journal of Medicine.
Laura is the Head of Clinical Innovation at Click Therapeutics, a biotechnology company that
develops and commercializes FDA approved software applications as medical treatments, focusing
on therapeutic strategy, evidence generation and real-world implementation.
Laura has been part of several successful FDA Breakthrough Designations for software as medical
devices and has overseen numerous research projects in CNS and oncology, tapping into the
potential of virtual trials to empower patients. Prior to Click, Laura was leading clinical operations at
Woebot Health and The Learning Corp.
Laura is keen on tackling health disparities by accelerating digital therapeutic development so that
clinically-proven, safe and effective solutions can be universally available to patients and their
providers.
Amir is an established neuroscientist specialized in digital medicine and clinical innovation. His strategic vision is empowered by real-world data that enable the discovery of clinical insights otherwise not possible solely based on conventional health records. Amir has boundless passion for accelerating novel therapies and creating a path for better patient experience. He brings an entrepreneurial zeal to the clinical world through disruptive technology and AI analytics from proof of concepts to scale-up solutions. Prior to pharma , Amir was a professor of Pediatrics and Epidemiology at Harvard Medical School and Harvard School of Public Health and served as a PI on numerous clinical trials with 200+ publications and conference presentations.
Dr. Risa Weisberg has devoted her career to developing and scientifically testing scalable interventions for common behavioral health problems. Her mission is to expand the reach of high-quality, science-based behavioral health treatment. She has over two decades of research, clinical, and leadership experience which she now brings to lead the clinical direction and research strategy of BehaVR at Chief Clinical Officer. Risa has a doctoral degree in Clinical Psychology from the University at Albany. She completed a doctoral internship and postdoctoral fellowship at Brown University. She is a Professor of Psychiatry at the Boston University School of Medicine and an Adjunct Professor of Family Medicine at the Alpert Medical School of Brown University. She is an expert in cognitive-behavioral therapy and acceptance and commitment therapies. As a primary care psychologist, Risa has broad experience in treatment development and implementation for common behavioral health problems including anxiety, depression, chronic pain, substance use disorder, and adaptation to living with other chronic medical difficulties. Her research has been funded by the National Institutes of Health, the Patient Centered Outcomes Research Institute, the Veterans Administration, and numerous foundations. Risa is a member of the Scientific Council of the Anxiety and Depression Association of America and a Fellow and former Board Member of the Association for Behavioral and Cognitive Therapies.
Dr. Andrew Welchman, Executive Vice President for Impact at ieso, is a Neuroscientist, former Professor at the University of Cambridge, and highly published academic. He has extensive speaking experience which includes addressing the House of Lords. He is responsible for ensuring ieso sets, measures and meets its ambitious social and economic impact goals.
ieso is a multi-award winning provider of evidence-based talking therapy for mood and anxiety disorders. Now available to over 20 million people, ieso was one of the first organisations to successfully develop and deploy evidence-based mental telehealthcare at scale. Leveraging real-world clinical data, ieso has pioneered the application of technologies such as deep-learning and natural language processing to improve the quality and cost-effectiveness of mental healthcare delivery.
Recognising the global demand-supply gap in mental healthcare provision, ieso has recently commenced the clinical development of a range of AI-enabled digital assessment and therapeutic solutions that it hopes will complement and extend human care delivery around the world.
Sean Kinsman, DPT serves as the Chief Clinical Officer at RecoveryOne, a leading
digital health innovator dedicated to improving health outcomes for recovery from
musculoskeletal (MSK) injuries of all types and reducing costs. Dr. Kinsman has been
instrumental in driving RecoveryOne’s expansion into clinical care and is the
architect behind their network of clinicians who service patients through their digital
treatment pathways. He is a Board Certified Orthopedic Clinical Specialist.
Prior to joining RecoveryOne, Dr. Kinsman contributed to the world-renowned “MICU
Study” while working in clinical practice at Johns Hopkins Hospital. The study focused
on the early mobilization of medically complicated patients in an intensive care unit
setting. Dr. Kinsman was also a key contributor to Johns Hopkins’ Hemophilia Clinic
and Cystic Fibrosis teams, managing long-term complications in both populations.
Dr. Kinsman’s previous experience also includes serving as part of a multi-
disciplinary team of Stanford physicians where he contributed to the creation of an
innovative, intensive recovery program for patients who developed dependence to
prescription opioids. The program averaged a 76% clinical success rate over six
years.
He previously also served as Clinic Director at Henning and Cole, a group of
outpatient therapy clinics in the Baltimore area. He earned his BS, MA and DPT at
Northeastern University, Boston, MA
Brendan is the Associate Director of Medical Affairs at Click Therapeutics. He
previously held a position in Medical Affairs at Pear Therapeutics. His experience
includes strategy development, publications, and evidence generation in clinical trials
and real-world studies. Brendan is a neuroscientist by training, earning a PhD from the
University of Vermont and serving as a postdoctoral fellow in the Yale Department of
Psychiatry.
Dr. Snipes is the Associate Director of Clinical Science at Click Therapeutics where she
leads a team focused on building efficacious prescription digital therapeutics for indications
including depression, schizophrenia, and migraine. She is a clinician-scientist with
experience advancing high quality, evidence-based psychological interventions in
healthcare, academia, and industry. She is a licensed clinical psychologist with training from
Henry Ford hospital and Kaiser Permanente Northern California in medically complex health
psychology, behavioral medicine, pain management, trauma, and women’s health. Dr.
Snipes also served as faculty of UMass Medical School.
Dave is an eo co-founder and investor. He oversees the end-to-end experience and product platform.
He is a recognized CX, digital product design, and marketing innovator in health, wealth and consumer
products and was the co-founder of two leading CX, marketing, and technology consultancies (BEAM and
Euro RSCG Circle).
Ted is an experienced media and technology professional with over 25 years of experience in product management and content development. Ted has held various executive, editorial and product management roles at AOL Canada, Yahoo!, and 4INFO where he was Vice President of Products. Starting in 2010 Ted began working as an independent consultant for early-stage companies developing data, online video, and television products and was instrumental in starting RevUp.com, an award-winning company based in Northern California that revolutionized political and non-profit fundraising. Ted is currently working as the Vice President of Product at Propeller Health, one of the top digital health companies in the world that are helping bring connected devices to asthma and COPD patients around the world.
Masashi is the Founder & Managing Partner at Kicker Ventures, an early-stage venture capital fund investing in the companies building the future of healthcare. Masashi is a believer in the role of technology transforming healthcare and is working to create a platform for entrepreneurs to maximize impact globally.
Rich is the Chief Commercial Officer at Click Therapeutics, a biotechnology company that develops and
commercializes FDA approved software applications as medical treatments. As Chief Commercial Officer
Rich oversees Market Access & Public Affairs, Marketing, Sales, Commercial Excellence, New Product
Planning and Commercial Partnership Success.
Rich’s background is in pricing, marketing, finance, and market access. Prior to joining Click, Rich held
various commercial roles at the pharmaceutical company Novo Nordisk. Most recently he was a Vice
President in Market Access, leading their Strategy and Innovation Team and their National Account
Team.
Rich believes in the power that digital therapeutics can bring to support patient outcomes and wants to
put his experience to work to put the industry’s and Click’s technology in the hands of as many patients
as possible.
Derk Arts MD, PhD has over fifteen years of experience in medicine, research and technology. He founded Castor to solve the biggest issues in clinical research: a lack of inclusivity, patient focus and impact of data. Castor enables sponsors worldwide to run patient-centric trials on a unified platform, that helps them maximize the impact of research data on patient lives.
Dr. Derk Arts believes the key to achieving lasting change in the industry is through scalability and standardization. Technology to run better trials and maximize the impact of data should be available to all researchers.
Over the past 12 months, Castor provided pro-bono support to over 300 COVID-19 trials, and provided the entire infrastructure for the World Health Organizations’ Solidarity Trials.
Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain, developing innovative technologies to monitor and stimulate the brain to help many patients in need. She was nominated by IESE Business School as one of the most influential entrepreneurs under 40 in Spain in 2010. She received the EU Prize for Women Innovators from the European Commission EC in 2014. In 2015 & 2016, she was named one of the most inspiring women on the Inspiring Fifty list in Europe. Ana continues breaking the barriers of science and technology in an impactful way with Business Ethics.
Soňa is the CEO and co-founder of Mindpax, a company that brings personalized digital care to patients with severe mental illnesses. Mindpax’s DTX for bipolar disorder will be the first product of its kind offered under German DiGA. With a background in finance, Soňa has 7 years of experience with clinical validation of digital health products. She has been cooperating with European and American leading research institutes and opinion leaders. Her ambition is to keep bringing to market meaningful digital solutions that will change mental illness treatment from a guessing game into a data-driven, continuous, targeted care.
Veera is a hands-on technology executive and business leader with a passion to bring positive change through the power of data and AI. He created Constant Therapy, an award-winning mobile app that uses artificial intelligence to help tens of thousands of people living with neurological conditions regain essential life skills.
Veera also successfully built a number of innovative products at other startups, including at a company acquired by Apple that developed the world’s fastest digital signal processor. He began his career as a Lead Engineer at Motorola developing mobile software and hardware products, and later, as Vice President of Engineering at a startup acquired by Motorola, developed software products that are now used worldwide to manage wireless networks. Veera has six technology patents and recently won TiE Boston’s Entrepreneur of the Year Award. He is an expert mentor at MassChallenge HealthTech and Insight Data Sciences, is a Charter Member of TiE Boston, and is a guest lecturer for Entrepreneurship at Questrom School of Business. Veera holds a PhD in electrical and computer engineering and a Master of Science degree in physics from Northwestern University, as well as a bachelor’s degree from the Indian Institute of Technology in Bombay.
Darren brings over 25 years of experience in developing, executing, and investing in growth strategies for emerging technology companies. Prior to joining Dreamit, Darren was a Board Member and held various operating positions at CIML LLC, a holding company for Channel Intelligence (acquired by Google). Darren also spent over 10 years as a private equity and venture investor at Actua, an investment and holding company for SaaS-based technology companies, where he served as a Managing Director. In the capacity of Managing Director, Darren was responsible for sourcing potential investment opportunities and leading the acquisition of portfolio companies, including business model diligence, transaction structuring and post- acquisition growth acceleration. Prior to Actua, Darren held various financial and operating positions. Darren started his career at Andersen in their enterprise division. Darren’s passion and unique strength is identifying promising companies, technologies and people, and helping them develop strategies to achieve their vision.
Location
Our venue for the 5th annual DTx East Summit will be held at the prestigious Boston Park Plaza Hotel.
Located in Boston’s Back Bay, this downtown hotel puts you within steps of Boston’s history, culture, shopping, dining, and entertainment.
We look forward to welcoming you to Boston in September.
Partner With Us
The DTx summits are the premier event series for senior executives from DTx companies, Pharma, Investors, HCPs, Payers and more.
DTx East 2022 is the 14th summit in the DTx series. The industry leaders and most exciting newcomers will be in attendance across an in-person and online event.
The DTx series provides a rare opportunity to showcase your business to a world-class audience. Spaces are limited this year, please contact our commercial manager, Sam (sam@greygreenmedia.com), to discuss your bespoke package.
Register for the Event
For pricing and booking options for DTx East 2022 please click the button to go to the registration page.